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Abstract
Ben Berkhout wins the 2008 Retrovirology Prize.
Editorial
Four years ago, Retrovirology inaugurated an annual prize
to recognize the achievements of a deserving retrovirolo-
gist [1]. The Prize is supported in part by the Ming K. Jeang
Foundation, a philanthropic charity based in Houston,
Texas, which has provided for scholarships at Houston
schools, at the University of Arizona, and at the Johns
Hopkins University School of Medicine. Previous winners
of the Retrovirology Prize include Stephen Goff [2], Joseph
Sodroski [3], and Karen Beemon [4]. A goal of the Retrovi-
rology Prize is to identify an outstanding mid-career scien-
tist who is close to the peak of his/her productivity and
who is expected to have many future years of high
achievement.
For 2008, the Editors of Retrovirology  selected Ben
Berkhout as the recipient of the Retrovirology Prize (Figure
1). Dr. Berkhout is Professor and Head of the Laboratory
of Experimental Virology at the Academic Medical Center
(AMC) of the University of Amsterdam, the Netherlands.
In the late 1980s, he was instrumental in changing the
paradigm of thinking on gene regulation. At a time when
the focus in eukaryotic transcription was on DNA-enhanc-
ers and DNA-binding proteins, Berkhout emerged to pro-
pose HIV-1 TAR RNA and the viral Tat protein as
prototypes of RNA and RNA-binding protein mediated
mammalian gene regulation [5]. That novel insight, focus-
ing on TAR as RNA rather than DNA, subsequently
directed efforts toward the cloning of additional TAR
RNA-binding proteins, such as the human TRBP protein
[6], which is now recognized to play a critical role in inter-
feron signaling, RNA interference, and micro-RNA bio-
genesis.
Dr. Berkhout's research on RNA has provided additional
important building blocks for many other aspects of our
current knowledge on HIV-1 replication. He has
employed a multi-disciplinary approach to research, com-
bining methods from molecular biology, biochemistry
and most importantly, virology. His research has
extended our insights into the mechanisms of transcrip-
tion, reverse transcription, drug-resistance, and RNA inter-
ference. For example, Berkhout and his colleagues have
been instrumental in the identification of the primer-acti-
vating signal (PAS) for reverse transcription, the descrip-
tion of the fitness defects in drug-resistant HIV-1 variants,
the first description of the in vivo evolution of a drug-
dependent HIV-1 variant under therapy pressure, the char-
acterization of the HIV-1 polyA hairpin structure and
mechanisms for regulating polyadenylation, the elucida-
tion of novel HIV-1 escape routes from RNAi-inhibition,
and the construction of a conditionally-live HIV-1 variant
as novel vaccination strategy, amongst other findings.
To understand Ben's career development and his motiva-
tions in science, I had an opportunity to converse with
him regarding his views on several questions. His
responses to a dozen of my queries are below.
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KTJ: Today's young people consider many other careers to
be more attractive than science. Tell us a bit about what
motivated and attracted you to science?
BB: During my chemistry study at the University of Lei-
den, I performed a traineeship in the Biochemistry depart-
ment where they worked on the mechanism of mRNA
translation in Escherichia coli. This was old-fashioned
biochemistry, ribosome isolations on Monday morning
in the cold room etc. It was fascinating to me that by mix-
ing several ingredients in a test tube you could learn some-
thing about this invisible process of nature. A little later
the introduction of molecular biology techniques greatly
accelerated this field, and our favorite model system was
the RNA bacteriophage MS2, one of the first viruses for
which an infectious cDNA clone had been generated. I
also performed my thesis work in Leiden, with Jan van
Duin, learning a few molecular RNA-tricks that are used
by the MS2 virus to regulate its gene expression.
KTJ: You didn't start by studying HIV; what changed your
mind during your postdoc days to turn to this field?
BB: I received a 1-year fellowship from the Dutch Cancer
Society to perform post-doctoral research at the Dana Far-
ber Cancer Institute of the Harvard Medical School. I
stayed there almost 3 years and learned a lot on the topic
of T cell immunology, but slowly came to realize that I
was missing RNA molecules, and viruses in particular. I
guess immunology remains too descriptive for me; at the
end of the day I want to learn something in molecular
terms that no one else knows. After a focused search, I
decided in 1988 to move into the HIV-1 field and ended
up in the laboratory of Kuan-Teh Jeang, by then a young
group leader at the National Institutes of Health in
Bethesda. That was the start of a very exciting and produc-
tive period. After a 5-year stay in the USA, my HIV-1
research was continued at the University of Amsterdam,
where I still reside.
KTJ: You are perhaps best known for your paper on TAR
as a nascent RNA target for Tat [5]. Walk us through on
your thinking at the time and what factors influenced your
thought?
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BB: The expertise of the laboratory was on HIV-1 and
HTLV-I, but mostly on the process of transcriptional regu-
lation by the LTR promoters. The TAR RNA hairpin motif
immediately attracted my interest, and the initial mutants
I generated were the ones that ended up in that 1989 Cell
paper. In fact, I designed a way to specifically mutate
structured RNA signals and not the underlying DNA
sequences, an idea that is largely based on a natural mech-
anism of regulated gene expression in bacteria that was
worked out by Charles Yanofsky at Stanford University.
This method also allows you to address kinetic aspects,
and that is how we ended up talking about the nascent
RNA transcript. We did not dare to use the word "RNA
enhancer" in that paper, but this term was subsequently
coined by Phil Sharp in an accompanying commentary.
Looking back, the combination of my RNA expertise and
the transcriptional focus of the lab turned out to be key in
this break-through. We have since kept an interest in the
functions of the TAR motif and the Tat protein.
KTJ:  Who are the scientists who have influenced your
career and how?
BB: Jan van Duin taught me how to design experiments
and how to think carefully and critically about the gener-
ated data. Kuan-Teh Jeang guided me on how to be inci-
sive and how to present results in writing and at meetings.
But in fact, many people have shaped my thinking and the
direction of my research.
KTJ: HIV research has been going on for more than a quar-
ter century, and a Nobel prize was just awarded for the dis-
covery of HIV-1. What do you see as the most important
question still facing HIV-1 research and what are your
thoughts on why we haven't made better progress?
BB: The one thing that is badly needed is an effective and
cheap vaccine that protects against HIV-1 transmission. It
is clear that there are currently no vaccine candidates that
look promising, and we should thus maximize the availa-
ble possibilities for prevention. It is obvious that the rela-
tively simple vaccination strategies that work for other
pathogens do not work for HIV-1. Despite all the funds
that have been available for HIV-1 vaccine research, it is
also fair to say that only a few approaches have been seri-
ously tried. The failure of these initial attempts, that is the
envelope protein and adenovirus-based vaccines, has
recently led to the suggestion to diversify our vaccination
approaches. I could not agree more, and we should be on
the lookout for young researchers with fresh ideas.
What went wrong? This is an interesting question that
may provide us with some important lessons for the
future. It may be that a "too early" focus on a certain vac-
cine candidate, which in itself is worth testing but cer-
tainly not worth putting all the money on. In fact, I think
that this is a particular problem of a densely populated
research area such as the HIV-1 field. The scientific crowd
usually follows a few leaders, without too much critical
thinking, and it may mean that momentum is built
around a track that turns out to be the wrong one. Diver-
sification and special focus on researchers that are new to
the field will be important. We have a few unique vaccine
projects running in the lab. I am not saying they will be
successful; it is all high-risk, but they are for sure different
from mainstream approaches. Let's hope that one of these
"crazy" ideas will lead the way to that protective vaccine.
KTJ: You have been an editor of Retrovirology for the past
5 years. What do you see in the future for Open Access
publishing and what do you consider as the advantages/
disadvantage of Open Access versus the traditional sub-
scription based publishing?
BB: From the start, I truly liked the basic idea that results
presented in an Open Access journal are available to the
reader anywhere on the globe without any financial or
other barrier other than access to the internet. A major
motivation for most authors to publish in an Open Access
journal is increased visibility and ultimately a citation
advantage. There is some research indicating that Open
Access articles are cited more frequently or earlier than
non-Open Access articles. I do not see any major disad-
vantage, and note that some of our traditional journals
have successfully moved to the Open Access format (e.g.
Nucleic Acids Research). The future is with Open Access
journals.
KTJ: You have published several notable papers in Retrovi-
rology [7-11]. How did you decide to publish in Retrovirol-
ogy? For the future direction of this journal, what would
you try to improve?
BB: As member of the editorial board of Retrovirology, we
of course wanted to present some of our own studies in
this new journal, although in the beginning Retrovirology
like all upstart journals was without an official impact fac-
tor. But, it was rewarding to see that when the first official
impact factor for Retrovirology was released it was a very
respectable number, 4.04 in 2007. This number ranked
the journal second on the Impact Factor list for virology
journals that publish original research articles (Retrovirol-
ogy ranks behind only the Journal of Virology). Indeed, over
the last few years, virologists around the world have
increasingly embraced Retrovirology, and we now receive
many more submissions than we can publish. I look for-
ward to further enhancing the quality threshold needed
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KTJ: We are perhaps at a tipping point in the globalization
of science. There are some predictions that by 2040, China
and India will be in the top three of world economic pow-
ers. How (what) do you think that American and Euro-
pean science should do (more) to engage science/
scientists from the emerging economies?
BB: Science is of course an international activity and we
usually meet our colleagues from all over the world at
meetings, and many promising collaborations do exist.
However, more should be done in particular with respect
to the training of young scientists. We are used to the (usu-
ally transient) brain drain of European post-docs to the
USA, but one should recognize the importance of such
training programs on a worldwide scale, and going in all
directions. A continuous dialogue between Western and
Eastern countries (and others) is very important to appre-
ciate the differences in cultural background that underlie
differences in perception of scientific issues, and to start
building bridges from there.
KTJ: Several recent articles have been written about the
aging of Western scientific leadership and the difficulties
confronted by younger scientists in garnering support.
What are your thoughts on these issues?
BB: The aging issue in itself should not be a problem,
as I know many sharp scientists with grey hair. Being
a mid-career scientist, at least according to the rules of
the Retrovirology Prize, I do indeed realize that it is of
utmost importance to facilitate the career of promis-
ing younger colleagues. In my own laboratory, I have
witnessed over the last few years that younger col-
leagues do take opportunities provided to them to
lead and supervise individual studies. For these stud-
ies, they should claim and do become the last (senior)
author for the published papers. This is the correct
thing to do, and senior authorship is a critical factor in
their attempts to compete for funding. We should get
rid of the automatic last authorship for professors and
departmental heads that usually lasts till their retire-
ment or even thereafter. Special funding possibilities
for young scientists are obviously important. We have
such a funding scheme in the Netherlands for promis-
ing post-docs (Veni-Vidi-Vici program), and the EU
has the Marie Curie fellowship program.
KTJ: One of the goals of the Retrovirology Prize is to pro-
mote the visibility of an outstanding mid-career scientist
so that he/she could do more over the next few years.
What are the next big ideas and projects that you would
like to pursue?
BB: We have over the years built a rather big research lab
with a core of basic HIV-1 studies and a few exciting
applied projects. The vaccine candidate that is based on a
conditionally replicating HIV-1 variant is now in macaque
studies (in a SIV version) and our antiviral gene therapy
based on RNA interference has recently moved into a pre-
clinical humanized mouse model. Thus, we have exciting
times ahead of us. We obviously will also continue the
basic HIV-1 replication studies, with a focus on under-
standing bits and pieces of the structure and function of
the HIV-1 RNA genome. Last but not least, we will con-
tinue some of the intriguing HIV-1 evolution studies that
my lab is well-known for. This theme fits with 2009 as the
bicentennial of Charles Darwin's birth and the 150th
anniversary of the publication of his seminal work 'On the
origin of Species'.
KTJ: In my office there is a quotation by Edmond Burke
'All that is necessary for the triumph of evil is that good
men do and say nothing'. If there is one thing that you
think needs to be said or done in science (or in society at
large), what would that be?
BB: It is obvious that large-scale approaches to scientific
discovery have arrived over the recent years, and these are
particularly powerful to address certain research ques-
tions. There is also a trend among funding bodies to spe-
cifically ask for large, multidisciplinary consortia. I am not
saying these recent trends are necessarily bad, but one
should not forget the individuals and smaller groups with
a strong track record, as they are frequently key in big dis-
coveries.
KTJ: With the understanding that it will be a long time in
the future, what would you like your headstone to read?
BB: How about "He was privileged to be paid to execute
his hobby"?
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